IMCR - Biogen Neurocrine and more are Bairds top picks for biotech in 2024
2024-01-04 14:57:40 ET
More on SPDR S&P Biotech ETF:
- Biopharmaceutical Stocks: The Rally Has Just Begun
- Get Ready For The New Biotech Bull Market
- Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble
- Biotechs post record gains in November amid improving outlook
- Biotechs rally with gene editing stocks among notable gainers
For further details see:
Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024